Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma (07-REV)

This study has been completed.
Sponsor:
Collaborators:
National Marrow Donor Program
Celgene Corporation
Information provided by (Responsible Party):
Center for International Blood and Marrow Transplant Research
ClinicalTrials.gov Identifier:
NCT00847639
First received: February 17, 2009
Last updated: April 2, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2014
  Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)